JP2009501745A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501745A5
JP2009501745A5 JP2008521869A JP2008521869A JP2009501745A5 JP 2009501745 A5 JP2009501745 A5 JP 2009501745A5 JP 2008521869 A JP2008521869 A JP 2008521869A JP 2008521869 A JP2008521869 A JP 2008521869A JP 2009501745 A5 JP2009501745 A5 JP 2009501745A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
substituted
compound according
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008521869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501745A (ja
Filing date
Publication date
Priority claimed from GBGB0514812.7A external-priority patent/GB0514812D0/en
Application filed filed Critical
Publication of JP2009501745A publication Critical patent/JP2009501745A/ja
Publication of JP2009501745A5 publication Critical patent/JP2009501745A5/ja
Pending legal-status Critical Current

Links

JP2008521869A 2005-07-19 2006-07-17 ヒスタミンh3受容体アンタゴニストおよび/または逆アゴニストとして有用なピペラジノン誘導体 Pending JP2009501745A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0514812.7A GB0514812D0 (en) 2005-07-19 2005-07-19 Compounds
PCT/EP2006/007036 WO2007009741A1 (en) 2005-07-19 2006-07-17 Piperazinone derivatives useful as histamine h3 receptor antagonists and/or inverse agonists

Publications (2)

Publication Number Publication Date
JP2009501745A JP2009501745A (ja) 2009-01-22
JP2009501745A5 true JP2009501745A5 (https=) 2009-09-10

Family

ID=34897470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008521869A Pending JP2009501745A (ja) 2005-07-19 2006-07-17 ヒスタミンh3受容体アンタゴニストおよび/または逆アゴニストとして有用なピペラジノン誘導体

Country Status (5)

Country Link
US (1) US20080275027A1 (https=)
EP (1) EP1906964A1 (https=)
JP (1) JP2009501745A (https=)
GB (1) GB0514812D0 (https=)
WO (1) WO2007009741A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0514811D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2152669A1 (en) 2007-05-03 2010-02-17 Cephalon, Inc. Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
BRPI0820432B8 (pt) * 2007-11-13 2021-05-25 Taisho Pharmaceutical Co Ltd derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados
EA018582B1 (ru) * 2007-11-20 2013-09-30 Янссен Фармацевтика Н.В. Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EP2220045A1 (en) * 2007-11-20 2010-08-25 Janssen Pharmaceutica, N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ,エルエルシー. 5−リポキシゲナーゼ活性化タンパク質阻害剤
JP5740838B2 (ja) * 2009-05-12 2015-07-01 大正製薬株式会社 フェニルピラゾール誘導体
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US10821106B2 (en) 2015-08-21 2020-11-03 Srx Cardio, Llc Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN108486155A (zh) * 2018-04-27 2018-09-04 中国医学科学院输血研究所 构建Doxycycline/Mifepristone诱导过表达的带有荧光蛋白标记基因的双诱导表达载体
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108088A (pt) * 2000-07-13 2004-04-06 Abbott Lab Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20060052597A1 (en) * 2002-10-22 2006-03-09 Best Desmond J Aryloxyalkylamine derivatives as h3 receptor ligands
GB0308333D0 (en) * 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2009501745A5 (https=)
JP2014508811A5 (https=)
JP2018515555A5 (https=)
JP2013505969A5 (https=)
JP2016520618A5 (https=)
JP2011519854A5 (https=)
JP2008501000A5 (https=)
JP2009534386A5 (https=)
JP2016503797A5 (https=)
JP2013513613A5 (https=)
JP2014511891A5 (https=)
JP2013510120A5 (https=)
JP2010540525A5 (https=)
JP2017505293A5 (https=)
JP2008500999A5 (https=)
JP2013523733A5 (https=)
JP2010155827A5 (https=)
JP2018514568A5 (https=)
JP2011512412A5 (https=)
JP2014528464A5 (https=)
JP2007520440A5 (https=)
JP2015526453A5 (https=)
JP2016540811A5 (https=)
JP2010506919A5 (https=)
JP2017509611A5 (https=)